<DOC>
	<DOC>NCT00374842</DOC>
	<brief_summary>The purpose of this study is to evaluate the immunogenicity and the safety of candidate vaccines compared to Fluarixâ„¢ administered intramuscularly in subjects aged 18-59 years</brief_summary>
	<brief_title>Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female aged 1859 years at the time of the first vaccination. Free of obvious health problems Use of nonregistered products Administration of immunemodifying drugs. Administration of vaccine 30 days before enrolment in study. Immunosuppressive or immunodeficient condition. Hypersensitivity to a previous dose of influenza vaccine Previous vaccination against influenza in 2006 Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality. History of confirmed influenza infection within the last 12 Months. Acute disease at the time of enrolment/vaccination. History of allergy or reactions likely to be exacerbated by any component of the vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Prophylaxis Influenza vaccine</keyword>
</DOC>